Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $50
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $51 to $50.
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $51 to $50.